The Crossover: Eli Lilly vs. Novo Nordisk
FY2020–FY2025 pharmaceutical revenue, USD billions
Eli Lilly FY2025
$65.2B
+45% YoY
Novo Nordisk FY2025
$46.7B
+11% YoY · Guiding −5% to −13% for 2026
Eli Lilly Novo Nordisk Novo figures converted from DKK at IRS annual average rates